| 1 |
34711126 | Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials. | 2022 Mar |
1 |
| 2 |
34984794 | Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment. | 2022 May |
2 |
| 3 |
35081865 | Linagliptin ameliorated interleukin-29-induced reduction of extracellular matrix genes through the nuclear factor erythroid 2-related factor 2 (Nrf2)/sry-type high-mobility-group box (SOX)-9 axis in an in vitro study on C-28/I2 chondrocytes. | 2022 Feb |
3 |
| 4 |
35086469 | DPP4 inhibitors: Could they be one of the solutions for COVID-19 patients with prediabetes? | 2022 Jan 27 |
1 |
| 5 |
35388920 | New enantioselective liquid chromatography method development and validation of dipeptidyl peptidase IV inhibitors using a macrocyclic glycopeptide (vancomycin) chiral stationary phase under polar ionic mode condition. | 2022 Jul |
2 |
| 6 |
32741073 | Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials. | 2021 Mar |
1 |
| 7 |
33030297 | A Single Second Shell Amino Acid Determines Affinity and Kinetics of Linagliptin Binding to Type 4 Dipeptidyl Peptidase and Fibroblast Activation Protein. | 2021 Feb 17 |
5 |
| 8 |
33185002 | Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. | 2021 Feb |
1 |
| 9 |
33236464 | Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study. | 2021 Mar |
1 |
| 10 |
33295687 | Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation. | 2021 Jan |
2 |
| 11 |
33348462 | Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease. | 2021 May 6 |
2 |
| 12 |
33479584 | Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial. | 2021 Jan |
2 |
| 13 |
33559704 | Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study. | 2021 Jun |
1 |
| 14 |
33667522 | Linagliptin mitigates experimental inflammatory bowel disease in rats by targeting inflammatory and redox signaling. | 2021 May 15 |
1 |
| 15 |
33881796 | Urinary dipeptidyl peptidase-4 protein is increased by linagliptin and is a potential predictive marker of urine albumin-to-creatinine ratio reduction in patients with type 2 diabetes. | 2021 Aug |
7 |
| 16 |
33927920 | Acute Pancreatitis Induced by Linagliptin: A Rare but Dangerous Side Effect. | 2021 Mar 25 |
1 |
| 17 |
34222724 | Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis. | 2021 Jun |
2 |
| 18 |
34287770 | DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020. | 2021 Nov |
1 |
| 19 |
34384428 | Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors. | 2021 Aug 12 |
1 |
| 20 |
34484112 | Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China. | 2021 |
2 |
| 21 |
34679685 | Plasma Nitrate Levels Are Related to Metabolic Syndrome and Are Not Altered by Treatment with DPP-4 Inhibitor Linagliptin: A Randomised, Placebo-Controlled Trial in Patients with Early Type 2 Diabetes Mellitus. | 2021 Sep 29 |
1 |
| 22 |
32166899 | Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase-4 inhibitor Linagliptin: A subanalysis from a randomized, placebo-controlled trial (RELEASE study). | 2020 Jul |
2 |
| 23 |
32206483 | Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial. | 2020 Apr |
1 |
| 24 |
32317005 | Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus. | 2020 Apr 21 |
1 |
| 25 |
32328953 | Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c ≤ 6.5% without Increasing Hypoglycemia: Pooled Analysis of Two Randomized Clinical Trials. | 2020 Jun |
1 |
| 26 |
32476255 | Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial. | 2020 Oct |
1 |
| 27 |
32493344 | Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial. | 2020 Jun 3 |
3 |
| 28 |
32546973 | A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers. | 2020 |
1 |
| 29 |
32661107 | Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA). | 2020 Sep |
1 |
| 30 |
32697283 | Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea. | 2020 Oct 1 |
2 |
| 31 |
32900785 | Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. | 2020 Nov |
1 |
| 32 |
32996028 | Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human. | 2020 Sep 29 |
2 |
| 33 |
33061298 | DPP-4 Inhibitor Linagliptin Ameliorates Oxidized LDL-Induced THP-1 Macrophage Foam Cell Formation and Inflammation. | 2020 |
4 |
| 34 |
33117158 | Soluble Dipeptidyl Peptidase-4 Induces Fibroblast Activation Through Proteinase-Activated Receptor-2. | 2020 |
2 |
| 35 |
28847268 | Design, Synthesis and Biological Evaluation of Spiro Cyclohexane-1,2- Quinazoline Derivatives as Potent Dipeptidyl Peptidase IV Inhibitors. | 2019 |
2 |
| 36 |
30136405 | DPP-4 inhibitors promote proliferation and migration of rat brain microvascular endothelial cells under hypoxic/high-glucose conditions, potentially through the SIRT1/HIF-1/VEGF pathway. | 2019 Mar |
2 |
| 37 |
30308704 | Linagliptin inhibits high glucose-induced transdifferentiation of hypertrophic scar-derived fibroblasts to myofibroblasts via IGF/Akt/mTOR signalling pathway. | 2019 Jan |
1 |
| 38 |
30312887 | A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. | 2019 Jan 30 |
1 |
| 39 |
30418475 | Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. | 2019 Jan 1 |
1 |
| 40 |
30466028 | Vascular protection of DPP-4 inhibitors in retinal endothelial cells in in vitro culture. | 2019 Jan |
1 |
| 41 |
30540657 | Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria. | 2019 Jun |
2 |
| 42 |
30607467 | Cardiovascular outcome trials of glucose-lowering medications: an update. | 2019 Mar |
2 |
| 43 |
30632171 | A new stability indicating reverse phase high performance liquid chromatography method for the determination of enantiomeric purity of a DPP-4 inhibitor drug linagliptin. | 2019 Apr |
1 |
| 44 |
30941884 | Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care. | 2019 Aug |
1 |
| 45 |
31018682 | Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial? | 2019 Jul |
2 |
| 46 |
31139140 | Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke. | 2019 |
2 |
| 47 |
31139534 | Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study. | 2019 Apr |
1 |
| 48 |
31149054 | THE IN VITRO CYTOTOXICITY, GENOTOXICITY AND OXIDATIVE DAMAGE POTENTIAL OF THE ORAL DIPEPTIDYL PEPTIDASE-4 INHIBITOR, LINAGLIPTIN, ON CULTURED HUMAN MONONUCLEAR BLOOD CELLS. | 2019 Jan-Mar |
4 |
| 49 |
31275243 | DPP-4 Inhibition and the Path to Clinical Proof. | 2019 |
1 |
| 50 |
31399442 | Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. | 2019 Oct |
1 |